FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283695478> ?p ?o ?g. }

• W4283695478 endingPage "1330" @default.
• W4283695478 startingPage "1330.2" @default.
• W4283695478 abstract "Background Rheumatoid arthritis (RA) is accompanied by a significant increase in the risk of infection and serious infections, among which pneumonia occupies a leading place. (1) The use of targeted anti-inflammatory drugs is accompanied by an additional increase in the risk of infectious complications. In this regard, vaccination is crucial in the management of such patients. Objectives To evaluate the safety and efficacy of the 13-valent pneumococcal vaccine in patients with RA undergoing various types of antirheumatic therapy. Methods The study included 60 patients with a reliable diagnosis of RA, according to the criteria of ACR/EULAR, among them 8 men and 52 women, average age 63 years (from 29 to 69 years) with disease activity at the time of inclusion of Das-28 – 4.9 (2.2-7.7), bionaive patients with insufficient response to DMARDs who will be prescribed tofacitinib (TOFA) for the first time or receiving TOFA for at least 3 months (30 patients in each group). Both groups of patients were further subdivided into two groups, 15 vaccinated and unvaccinated patients in each. The exclusion criteria were: age over 70 years; patients with infectious diseases in the acute stage; having a history of intolerance to diphtheria toxoid, patients who had previously been vaccinated with pneumococcal vaccines. For the prevention of pneumococcal infection, a pneumococcal 13-valent polysaccharide conjugated adsorbed vaccine was used. Visits to assess the condition were made in the period of 0-3-12 months. The activity of the disease was assessed by the DAS 28, CDAI, SDAI indices. Results Among vaccinated patients with PCV 13 the most common adverse events were: pain at the injection site (16%), fever up to 37.6C (13%), redness at the injection site (6%), infiltration at the injection site (2%), myalgia (2%). These adverse events resolved spontaneously within 3 days. In a comparative assessment of infectious events during 12 months before vaccination and the next 12 months after it, there were no significant differences between vaccinated and unvaccinated patients. In patients who had a history of pneumococcal etiology infections after vaccination, the incidence decreased by 33%. Conclusion Vaccination against pneumococcal infection is a safe and effective method of preventing pneumococcal infection in patients with rheumatoid arthritis. References [1]Koivuniemi R., Leirisalo-Repo M., Suomalainen R., etc. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol 2006; 35)4): 273-6 Disclosure of Interests Galina Lukina Speakers bureau: Ebbvie, Biocad, Pfizer, Roche, Dzhamilya Murtazalieva: None declared, Ekaterina Koltsova: None declared, Mikhail Kostinov: None declared, Anna Shmitko: None declared, Dmitry Blagovidov: None declared, Evgeniy Zhilyaev Speakers bureau: Ebbvie, Biocad, Pfizer, Roche" @default.
• W4283695478 created "2022-06-30" @default.
• W4283695478 creator A5004986878 @default.
• W4283695478 creator A5016079587 @default.
• W4283695478 creator A5019805478 @default.
• W4283695478 creator A5026606284 @default.
• W4283695478 creator A5040123849 @default.
• W4283695478 creator A5065898987 @default.
• W4283695478 creator A5077006185 @default.
• W4283695478 date "2022-05-23" @default.
• W4283695478 modified "2023-09-26" @default.
• W4283695478 title "AB0403 EVALUATION OF THE SAFETY AND EFFICACY OF 13-VALENT PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS" @default.
• W4283695478 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2530" @default.
• W4283695478 hasPublicationYear "2022" @default.
• W4283695478 type Work @default.
• W4283695478 citedByCount "0" @default.
• W4283695478 crossrefType "journal-article" @default.
• W4283695478 hasAuthorship W4283695478A5004986878 @default.
• W4283695478 hasAuthorship W4283695478A5016079587 @default.
• W4283695478 hasAuthorship W4283695478A5019805478 @default.
• W4283695478 hasAuthorship W4283695478A5026606284 @default.
• W4283695478 hasAuthorship W4283695478A5040123849 @default.
• W4283695478 hasAuthorship W4283695478A5065898987 @default.
• W4283695478 hasAuthorship W4283695478A5077006185 @default.
• W4283695478 hasBestOaLocation W42836954781 @default.
• W4283695478 hasConcept C126322002 @default.
• W4283695478 hasConcept C203014093 @default.
• W4283695478 hasConcept C22070199 @default.
• W4283695478 hasConcept C2777575956 @default.
• W4283695478 hasConcept C2777914695 @default.
• W4283695478 hasConcept C2779301066 @default.
• W4283695478 hasConcept C2779664119 @default.
• W4283695478 hasConcept C2779892413 @default.
• W4283695478 hasConcept C2781253189 @default.
• W4283695478 hasConcept C3020803494 @default.
• W4283695478 hasConcept C501593827 @default.
• W4283695478 hasConcept C71924100 @default.
• W4283695478 hasConcept C86803240 @default.
• W4283695478 hasConcept C89423630 @default.
• W4283695478 hasConceptScore W4283695478C126322002 @default.
• W4283695478 hasConceptScore W4283695478C203014093 @default.
• W4283695478 hasConceptScore W4283695478C22070199 @default.
• W4283695478 hasConceptScore W4283695478C2777575956 @default.
• W4283695478 hasConceptScore W4283695478C2777914695 @default.
• W4283695478 hasConceptScore W4283695478C2779301066 @default.
• W4283695478 hasConceptScore W4283695478C2779664119 @default.
• W4283695478 hasConceptScore W4283695478C2779892413 @default.
• W4283695478 hasConceptScore W4283695478C2781253189 @default.
• W4283695478 hasConceptScore W4283695478C3020803494 @default.
• W4283695478 hasConceptScore W4283695478C501593827 @default.
• W4283695478 hasConceptScore W4283695478C71924100 @default.
• W4283695478 hasConceptScore W4283695478C86803240 @default.
• W4283695478 hasConceptScore W4283695478C89423630 @default.
• W4283695478 hasIssue "Suppl 1" @default.
• W4283695478 hasLocation W42836954781 @default.
• W4283695478 hasOpenAccess W4283695478 @default.
• W4283695478 hasPrimaryLocation W42836954781 @default.
• W4283695478 hasRelatedWork W1985020513 @default.
• W4283695478 hasRelatedWork W2028865972 @default.
• W4283695478 hasRelatedWork W2046569203 @default.
• W4283695478 hasRelatedWork W2075491595 @default.
• W4283695478 hasRelatedWork W2134578591 @default.
• W4283695478 hasRelatedWork W2172236508 @default.
• W4283695478 hasRelatedWork W2588622272 @default.
• W4283695478 hasRelatedWork W2624608577 @default.
• W4283695478 hasRelatedWork W3216036605 @default.
• W4283695478 hasRelatedWork W3515805 @default.
• W4283695478 hasVolume "81" @default.
• W4283695478 isParatext "false" @default.
• W4283695478 isRetracted "false" @default.
• W4283695478 workType "article" @default.